- The FDA has granted Orphan Drug Designation to Novartis AG's NVS NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer.
- NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor cells and modulate the tumor microenvironment.
- A Phase 2 study is ongoing, and a Phase 3 trial in the first-line metastatic pancreatic ductal carcinoma is planned to start enrolling patients later in 2021.
- Price Action: NVS shares are up 0.27% at $91.21 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
